CN1521161A - Preparation of Oxaliplatin - Google Patents

Preparation of Oxaliplatin Download PDF

Info

Publication number
CN1521161A
CN1521161A CNA031039081A CN03103908A CN1521161A CN 1521161 A CN1521161 A CN 1521161A CN A031039081 A CNA031039081 A CN A031039081A CN 03103908 A CN03103908 A CN 03103908A CN 1521161 A CN1521161 A CN 1521161A
Authority
CN
China
Prior art keywords
oxaliplatin
platinum
dach
cis
cyclohexanediamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA031039081A
Other languages
Chinese (zh)
Other versions
CN1221560C (en
Inventor
普绍平
高桂桂
刘祝东
何键
余尧
刘伟平
谌喜珠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kunming Institute of Precious Metals
Original Assignee
Kunming Institute of Precious Metals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kunming Institute of Precious Metals filed Critical Kunming Institute of Precious Metals
Priority to CN 03103908 priority Critical patent/CN1221560C/en
Publication of CN1521161A publication Critical patent/CN1521161A/en
Application granted granted Critical
Publication of CN1221560C publication Critical patent/CN1221560C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

The present invention is the preparation process of antitumor medicine Oxaliplatin C8H14N2O4Pt. In the technological process, cis-dichloro cyclohexanediamine-platinum (II) or cis-diidio cyclohexanediamine-platinum (II) as initiator is made to react with silver oxalate in lucifugous condition at 40-75 deg.c to obtain water solution of Oxaliplatin; and the water solution is further decompression concentrated to obtain solid Oxaliplatin product. The said Oxaliplatin preparation process is short, high in production efficiency and easy in operation.

Description

奥沙利铂的制备Preparation of Oxaliplatin

技术领域technical field

本发明涉及抗肿瘤药物奥沙利铂的合成制备。The invention relates to the synthesis and preparation of antitumor drug oxaliplatin.

背景技术Background technique

奥沙利铂属铂族金属配合物,是继顺铂、卡铂之后的新一代铂类抗肿瘤药物。奥沙利铂又名草酸铂,英文名Oxaliplatin,缩写为L-OHP,全称为顺式-草酸(反式-(-)-1,2-环己二胺)合铂(II)[cis-oxalato(trans-(1R,2R)-(-)-1,2-diaminocyclohexane)platinum(II)],分子量为397.33,化学结构式:Oxaliplatin is a platinum group metal complex and is a new generation of platinum-based antineoplastic drugs after cisplatin and carboplatin. Oxaliplatin, also known as oxaliplatin, English name Oxaliplatin, abbreviated as L-OHP, full name cis-oxalic acid (trans-(-)-1,2-cyclohexanediamine) platinum(II)[cis- oxalato(trans-(1R,2R)-(-)-1,2-diaminocyclohexane)platinum(II)], molecular weight is 397.33, chemical structural formula:

Figure A0310390800031
Figure A0310390800031

奥沙利铂最早由瑞士Debiopharm公司开发,1997年在法国获批准应用于临床,主要用于治疗转移性大肠直肠癌。目前已在多个国家或地区获批准应用于临床。美国FDA也认可批准治疗大肠直肠癌。奥沙利铂是以草酸根及反式-(-)-1,2环己胺(DACH)作配体与二价金属铂形成的配合物。《贵金属》2000年第21卷第1期刊载的“草酸铂的合成及其结构表征”一文中,报道了奥沙利铂的合成方法,其合成路线为:Oxaliplatin was first developed by Debiopharm in Switzerland and was approved for clinical use in France in 1997, mainly for the treatment of metastatic colorectal cancer. At present, it has been approved for clinical application in many countries or regions. The US FDA also approves the treatment of colorectal cancer. Oxaliplatin is a complex formed with oxalate and trans-(-)-1,2 cyclohexylamine (DACH) as ligands and divalent metal platinum. In the article "Synthesis and Structural Characterization of Platinum Oxalate" published in No. 1, Volume 21, 2000 of "Precious Metals", the synthesis method of oxaliplatin is reported, and the synthesis route is as follows:

Figure A0310390800032
Figure A0310390800032

《Drugs of the future》1989年第14卷第6期刊载的“Oxaliplatin”一文中也报道了奥沙利铂的合成方法,其工艺路线为:"Drugs of the future" also reported the synthesis method of Oxaliplatin in the article "Oxaliplatin" published in Volume 14, Issue 6, 1989. The process route is:

上述两篇文献公开的奥沙利铂的合成是以顺式-二氯环己二胺合铂(II)或顺式-二碘环己二胺合铂(II)为中间体,加硝酸银水解反应,然后过滤除去氯化银或碘化银沉淀,母液中加入草酸钾或草酸钠,反应后生成奥沙利铂水溶液,减压浓缩得奥沙利铂产品。这种制备技术由于采用多步化学反应,导致工艺流程冗长复杂,产品收率较低。The synthesis of oxaliplatin disclosed in the above two documents is to use cis-dichlorocyclohexanediamine platinum (II) or cis-diiodocyclohexanediamine platinum (II) as an intermediate, and add silver nitrate Hydrolysis reaction, and then filter to remove silver chloride or silver iodide precipitation, add potassium oxalate or sodium oxalate to the mother liquor, generate oxaliplatin aqueous solution after reaction, and concentrate under reduced pressure to obtain oxaliplatin product. Due to the use of multi-step chemical reactions in this preparation technology, the process flow is lengthy and complicated, and the product yield is low.

发明内容Contents of the invention

本发明目的在于提供一种工艺流程简便的奥沙利铂制备方法。The object of the present invention is to provide a kind of preparation method of oxaliplatin with simple and convenient technological process.

本发明的奥沙利铂制备方法,采用顺式-二氯(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)Cl2,其结构式为:The preparation method of oxaliplatin of the present invention adopts cis-dichloro (trans-(-)-1,2-cyclohexanediamine) platinum (II), its molecular formula Pt(DACH)Cl 2 , its structural formula for:

Figure A0310390800041
Figure A0310390800041

或顺式-二碘(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)I2,其结构式为:Or cis-diiodo(trans-(-)-1,2-cyclohexanediamine) platinum(II), its molecular formula is Pt(DACH)I 2 , and its structural formula is:

Figure A0310390800042
Figure A0310390800042

在40℃至75℃避光条件下与草酸银Ag2C2O4反应,两者的反应摩尔比为1∶1,得到奥沙利铂水溶液。React with silver oxalate Ag 2 C 2 O 4 under the condition of 40°C to 75°C protected from light, and the reaction molar ratio of the two is 1:1 to obtain an aqueous solution of oxaliplatin.

将上述反应制备得到的奥沙利铂水溶液置于蒸发容器中并降低蒸发容器内的压力,于40℃至75℃水浴加热浓缩奥沙利铂水溶液,可以得到奥沙利铂固体产品。The oxaliplatin aqueous solution prepared by the above reaction is placed in an evaporation container, the pressure in the evaporation container is reduced, and the oxaliplatin aqueous solution is heated and concentrated in a water bath at 40° C. to 75° C. to obtain a solid oxaliplatin product.

相应的化学反应式为:The corresponding chemical reaction formula is:

                 

        或 or

本发明的奥沙利铂制备方法与上述文献报道的方法相比,缩短了生产周期,简化了生产工序,操作简便,生产效率提高近10个百分点。Compared with the method reported in the above literature, the preparation method of oxaliplatin of the present invention shortens the production cycle, simplifies the production process, is easy to operate, and increases the production efficiency by nearly 10 percentage points.

一、试剂及材料1. Reagents and materials

1.Pt(DACH)I2,分子量为:563.08。采用将K2PtCl4溶于适量水中,加入过量的分析纯KI,30min后等当量加入DACH,2小时后过滤沉出的黄色沉淀,分别用水、乙醇及丙酮洗涤,70℃干燥,得Pt(DACH)I2产品,纯度≥98%。1. Pt(DACH)I 2 , molecular weight: 563.08. Dissolve K 2 PtCl 4 in an appropriate amount of water, add excess analytically pure KI, add DACH equivalently after 30 minutes, filter the precipitated yellow precipitate after 2 hours, wash with water, ethanol and acetone respectively, and dry at 70°C to obtain Pt( DACH) I 2 product, purity ≥ 98%.

2.Pt(DACH)Cl2,分子量为:380.17。采用将K2PtCl4溶于适量水中,等当量加入DACH,反应2小时,过滤析出的黄色沉淀,分别用水、乙醇及丙酮洗涤,70℃干燥,得Pt(DACH)Cl2产品,纯度≥98%。2. Pt(DACH)Cl 2 , molecular weight: 380.17. Dissolve K 2 PtCl 4 in an appropriate amount of water, add DACH in an equivalent amount, react for 2 hours, filter the precipitated yellow precipitate, wash with water, ethanol and acetone, and dry at 70°C to obtain Pt(DACH)Cl 2 product with a purity of ≥98 %.

3.Ag2C2O4(市售,分析纯)3.Ag 2 C 2 O 4 (commercially available, analytically pure)

4.KI(分析纯),乙醇(分析纯),丙酮(分析纯)。4. KI (analytical pure), ethanol (analytical pure), acetone (analytical pure).

具体实施方式Detailed ways

实施例1Example 1

5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在40℃左右,等当量加入Ag2C2O4,避光搅拌反应6小时,然后过滤除去AgCl沉淀,母液减压浓缩,得到4.2克白色结晶样品,产率为81%。经元素分析、红外等分析,结构与目标化合物一致。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 40°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 6 hours in the dark, then filter to remove the AgCl precipitate, and concentrate the mother liquor under reduced pressure. A 4.2 g sample of white crystals was obtained with a yield of 81%. The structure was consistent with the target compound by elemental analysis and infrared analysis.

元素分析:测定值为C:24.21%,H:3.57%,N:7.01%,Pt:49.04%。理论值为C:24.19%,H:3.55%,N:7.05%,Pt:49.09%。组成与理论吻合。Elemental analysis: measured values are C: 24.21%, H: 3.57%, N: 7.01%, Pt: 49.04%. Theoretical values are C: 24.19%, H: 3.55%, N: 7.05%, Pt: 49.09%. The composition agrees with the theory.

红外吸收光谱:IR光谱(KBr压片cm-1):N-H(3212,3171,1610);C-H(3095,2932,2863,1447);C=O(1702,1664);C-O(1379);C-C(916,909);Pt-N(480);Pt-O(310)。Infrared absorption spectrum: IR spectrum (KBr pellet cm -1 ): NH (3212, 3171, 1610); CH (3095, 2932, 2863, 1447); C=O (1702, 1664); CO (1379); CC (916,909); Pt-N (480); Pt-O (310).

质谱(MS):采用快原子轰击法,测定结果见表1。Mass Spectrometry (MS): The fast atom bombardment method was adopted, and the measurement results are shown in Table 1.

   表1     m/e     相对丰度     相应碎片     398     100     分子离子峰     353     3     [Pt(DACH)CO2]+     309     15     [Pt(DACH)]2+     115     5     [C6H15N2]+     98     17     [C6H12N]+     81     10     [C6H9]+ Table 1 m/e relative abundance Corresponding Fragment 398 100 molecular ion peak 353 3 [Pt(DACH)CO 2 ] + 309 15 [Pt(DACH)] 2+ 115 5 [C 6 H 15 N 2 ] + 98 17 [C 6 H 12 N] + 81 10 [C 6 H 9 ] +

实施例2Example 2

5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在75℃左右,等当量加入Ag2C2O4,避光搅拌反应4小时,然后过滤除去AgCl沉淀,母液减压浓缩,得到4.12克白色结晶样品,产率为79%。经元素分析、红外、质谱等分析,结构与目标化合物一致。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 75°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 4 hours in the dark, then filter to remove the AgCl precipitate, and concentrate the mother liquor under reduced pressure. A 4.12 g sample of white crystals was obtained with a yield of 79%. The structure is consistent with the target compound by elemental analysis, infrared, mass spectrometry and other analysis.

元素分析:测定值为C:24.23%,H:3.56%,N:7.04%,Pt:49.12%。理论值为C:24.19%,H:3.55%,N:7.05%,Pt:49.09%。组成与理论吻合。Elemental analysis: measured values are C: 24.23%, H: 3.56%, N: 7.04%, Pt: 49.12%. Theoretical values are C: 24.19%, H: 3.55%, N: 7.05%, Pt: 49.09%. The composition agrees with the theory.

红外吸收光谱:IR光谱(KBr压片cm-1):N-H(3217,3176,1613);C-H(3099,2936,2867,1450);C=O(1710,1669);C-O(1382);C-C(917,912);Pt-N(480):Pt-O(310)。Infrared absorption spectrum: IR spectrum (KBr pellet cm -1 ): NH (3217, 3176, 1613); CH (3099, 2936, 2867, 1450); C=O (1710, 1669); CO (1382); CC (917,912); Pt-N(480):Pt-O(310).

质谱(MS):采用快原子轰击法,测定结果见表2。Mass Spectrometry (MS): The fast atom bombardment method was adopted, and the measurement results are shown in Table 2.

   表2     m/e     相对丰度     相应碎片     398     100     分子离子峰     309     17     [Pt(DACH)]2+     115     4     [C6H15N2]+     98     25     [C6H12N]+     81     12     [C6H9]+ Table 2 m/e relative abundance Corresponding Fragment 398 100 molecular ion peak 309 17 [Pt(DACH)] 2+ 115 4 [C 6 H 15 N 2 ] + 98 25 [C 6 H 12 N] + 81 12 [C 6 H 9 ] +

实施例3Example 3

5克Pt(DACH)Cl2溶于适量去离子水中,温度控制在55℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品4.21克,结构与目标化合物一致,产率为81%。Dissolve 5 grams of Pt(DACH)Cl 2 in an appropriate amount of deionized water, control the temperature at about 55°C, add an equivalent amount of Ag 2 C 2 O 4 , and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 4.21 is obtained. gram, the structure is consistent with the target compound, and the yield is 81%.

实施例4Example 4

9克Pt(DACH)I2溶于适量去离子水中,温度控制在40℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.12克,结构与目标化合物一致,产率为82%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 40°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 5.12 is obtained. gram, the structure is consistent with the target compound, and the yield is 82%.

实施例5Example 5

9克Pt(DACH)I2溶于适量去离子水中,温度控制在75℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.02克,结构与目标化合物一致,产率为80.5%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 75°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1 to obtain sample 5.02 gram, the structure is consistent with the target compound, and the yield is 80.5%.

实施例6Example 6

9克Pt(DACH)I2溶于适量去离子水中,温度控制在55℃左右,等当量加入Ag2C2O4,避光搅拌反应5小时,之后的操作同实施例1,得样品5.19克,结构与目标化合物一致,产率为83.1%。Dissolve 9 grams of Pt(DACH)I 2 in an appropriate amount of deionized water, control the temperature at about 55°C, add Ag 2 C 2 O 4 in an equivalent amount, and stir for 5 hours in the dark. The subsequent operations are the same as in Example 1, and sample 5.19 is obtained. gram, the structure is consistent with the target compound, and the yield is 83.1%.

Claims (2)

1.抗肿瘤药物奥沙利铂的制备方法,其结构式如下:1. the preparation method of antitumor drug oxaliplatin, its structural formula is as follows:
Figure A031039080002C1
Figure A031039080002C1
其特征在于采用顺式-二氯(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)Cl2,其结构式为:It is characterized in that it adopts cis-dichloro (trans-(-)-1,2-cyclohexanediamine) platinum (II), its molecular formula is Pt(DACH)Cl 2 , and its structural formula is:
Figure A031039080002C2
Figure A031039080002C2
或顺式-二碘(反式-(-)-1,2-环己二胺)合铂(II),其分子式Pt(DACH)I2,其结构式为:Or cis-diiodo(trans-(-)-1,2-cyclohexanediamine) platinum(II), its molecular formula is Pt(DACH)I 2 , and its structural formula is:
Figure A031039080002C3
Figure A031039080002C3
在避光条件下40℃至75℃与草酸银Ag2C2O4反应,两者的反应摩尔比为1∶1。React with silver oxalate Ag 2 C 2 O 4 at 40°C to 75°C under dark conditions, and the molar ratio of the two is 1:1.
2.根据权利要求1所述的奥沙利铂制备方法,其特征在于将奥沙利铂水溶液置于蒸发容器中并降低蒸发容器内的压力,于40℃至75℃水浴加热浓缩奥沙利铂水溶液,得到奥沙利铂固体产品。2. The preparation method of oxaliplatin according to claim 1, characterized in that the aqueous solution of oxaliplatin is placed in an evaporation vessel and the pressure in the evaporation vessel is reduced, and concentrated oxaliplatin is heated in a water bath at 40° C. to 75° C. Platinum aqueous solution to obtain oxaliplatin solid product.
CN 03103908 2003-01-30 2003-01-30 Preparation of oxaliplatin Expired - Fee Related CN1221560C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 03103908 CN1221560C (en) 2003-01-30 2003-01-30 Preparation of oxaliplatin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 03103908 CN1221560C (en) 2003-01-30 2003-01-30 Preparation of oxaliplatin

Publications (2)

Publication Number Publication Date
CN1521161A true CN1521161A (en) 2004-08-18
CN1221560C CN1221560C (en) 2005-10-05

Family

ID=34282115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 03103908 Expired - Fee Related CN1221560C (en) 2003-01-30 2003-01-30 Preparation of oxaliplatin

Country Status (1)

Country Link
CN (1) CN1221560C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114441671A (en) * 2021-12-23 2022-05-06 北京悦康科创医药科技股份有限公司 Method for determining content of platinum impurity cyclohexanediamine dihydrate in oxaliplatin by combination of HPLC-ICP-MS

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114441671A (en) * 2021-12-23 2022-05-06 北京悦康科创医药科技股份有限公司 Method for determining content of platinum impurity cyclohexanediamine dihydrate in oxaliplatin by combination of HPLC-ICP-MS
CN114441671B (en) * 2021-12-23 2023-05-30 北京悦康科创医药科技股份有限公司 Method for measuring content of cyclohexanediamine dihydrate platinum impurities in oxaliplatin by HPLC-ICP-MS (high performance liquid chromatography-inductively coupled plasma-mass spectrometry) combination

Also Published As

Publication number Publication date
CN1221560C (en) 2005-10-05

Similar Documents

Publication Publication Date Title
Canil et al. Photocytotoxic Pt (iv) complexes as prospective anticancer agents
HK1055746A1 (en) Process of preparing platinum compound
CN1285603C (en) Synthesis of oxaliplatin
CN1196706C (en) Method for preparing platinum compound
CN1221560C (en) Preparation of oxaliplatin
CN101830933B (en) Novel method for synthesizing antitumor medicament platinum
CN101768191A (en) Novel method for synthesizing anti-tumor drug Miriplatin
CN1948323A (en) Platinum (II)- anticancer compound using 2-hydroxy-1,3-propane diamine as carrier group
CN101918379B (en) Platinum complex compound and utilization of the same
CN106883251A (en) A kind of many pyridine copper complexes of amino acid and its preparation method and application
CN114106052A (en) Tetranuclear platinum carboxylate, synthetic method and application thereof in preparation of platinum black
WO2021051709A1 (en) Osmium complex, preparation method therefor and use thereof
CN100582115C (en) Novel method for synthesizing antineoplastic medicine carboplatin
CN101234788A (en) Method for synthesizing antineoplastic medicine cisplatin
CN114437133B (en) Iridium-containing complex and preparation method thereof
JP2007512318A (en) Platinum (II) complex and process and use of the complex
RU2457838C1 (en) Method of obtaining trans-1,2-diaminocyclohexane tetrachloroplatinum (iv)
CN101343291B (en) Novel method for preparing oxaliplatin
CN101302236A (en) Novel method for synthesizing antineoplastic medicine nedaplatin
JP2012530737A (en) Process for producing 1,2-diamino-cyclohexane-platinum (II) complex
CN1203080C (en) Antitumour platinum (II) compound using camphor acid radical as ligand
CN1260221C (en) Method for preparing platinum(II) metal complex eptaplatin
CN101475599B (en) Novel method for synthesizing antineoplastic medicament nedaplatin
CN1263764C (en) Platinum complex having anticancer activity
CN105218589A (en) A kind of synthetic method of oxaliplatin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20051005

Termination date: 20150130

EXPY Termination of patent right or utility model